ITGB7: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It’s the GeneMedi’s summary page for Target/Biomarker Introduction of ITGB7. The page also collects GeneMedi’s different modalities and formats products for ITGB7 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the ITGB7 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a protein that is a member of the integrin superfamily. Members of this family are adhesion receptors that function in signaling from the extracellular matrix to the cell. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. The encoded protein forms dimers with an alpha4 chain or an alphaE chain and plays a role in leukocyte adhesion. Dimerization with alpha4 forms a homing receptor for migration of lymphocytes to the intestinal mucosa and Peyer’s patches. Dimerization with alphaE permits binding to the ligand epithelial cadherin, a calcium-dependent adhesion molecule. Alternate splicing results in multiple transcript variants. Additional alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. [provided by RefSeq, Sep 2013]

Target ID

GM-T14065

Target Name

ITGB7

Gene ID

3695

Gene Official Name

ITGB7

Gene Alias

Protein Sub-location

Transmembrane Protein

Category

Therapeutics Target, Immuno-oncology Target, INN Index

Pre-made ITGB7-specific INN-index biosimilar (antibody&conjugates)-Vedolizumab, Etrolizumab

Anti-ITGB7 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Filters Sort results
Reset Apply
Cat No.
Products Name (INN Index)
INN Name
Previous Name
Target
Format
Order
Pre-Made Etrolizumab biosimilar, Whole Mab: Anti-ITGA4;ITGB7;ITGAE;ITGB7 therapeutic antibody
Etrolizumab
NA
ITGA4_ITGB7&ITGAE_ITGB7
Whole mAb
Pre-Made Vedolizumab biosimilar, Whole mAb, Anti-ITGA4;ITGB7 Antibody: Anti-CD49D/IA4 therapeutic antibody
Vedolizumab
NA
ITGA4_ITGB7
Whole mAb

Anti-ITB7/ ITGB7 antibody for FACS & in-vivo assay| GMab

Pre-made anti-ITGB7 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-ITGB7 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Filters Sort results
Reset Apply
Cat No.
Antibody Name
Format
Classified by tag
Order
Anti-ITGB7 monoclonal antibody
mab
FACS/Biofunctional Antibody, Therapeutics Target antibody